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Abstract
Background: HCV causes acute and chronic hepatitis which can eventually lead to permanent liver damage
hepatocellular carcinoma and death. HCV glycoproteins play an important role in HCV entry by binding with CD81
receptors. Hence inhibition of virus at entry step is an important target to identify antiviral drugs against HCV.
Methods and result: The present study elaborated the role of CD81 and HCV glycoprotein E2 in HCV entry using
retroviral pseudo-particles of 3a local genotype. Our results demonstrated that HCV specific antibody E2 and host
antibody CD81 showed dose- dependent inhibition of HCV entry. HCV E2 antibody showed 50% reduction at a
concentration of 1.5 ± 1 μg while CD81 exhibited 50% reduction at a concentration of 0.8 ± 1 μg. In addition, data
obtained with HCVpp were also confirmed with the infection of whole virus of HCV genotype 3a in liver cells.
Conclusion: Our data suggest that HCV specific E2 and host CD81 antibodies reduce HCVpp entry and full length viral
particle and combination of host and HCV specific antibodies showed synergistic effect in reducing the viral titer.
Background
HCV is a major health problem that infects 350 million
people worldwide and 10 million people in Pakistan [1].
HCV infection is mainly restricted to hepatocytes, and
since most of the infected individuals fail to spontaneously
clear the virus from the liver, this leads to a chronic infec-
tion that can evolve towards liver fibrosis, cirrhosis and
hepatocellular carcinoma over a period of decades [2]. The
current standard therapy is Pegylated interferon and riba-
virin, which shows poor tolerability and is only capable of
attaining a sustained viral response in half of patients due
to resistance mutations, adverse side effects and high cost
[3].
HCV is a small enveloped virus with a positive-sense,
single-stranded RNA genome that encodes a large poly-
protein of 3010 amino acids. The polyprotein is co- and
post-translationally processed by cellular and virally
encoded proteases to produce four structural (Core, E1,
E2 and P7) and six non-structural proteins (NS2, NS3,
N S 4 A ,N S 4 B ,N S 5 A ,N S 5 B )[ 4 , 5 ] .A m o n gt h es t r u c t u r a l
protein, HCV envelop protein E1 and E2 are highly glyco-
sylated and play an important role in cell entry. HCV NS3
serine protease and NS5b RNA dependent RNA polymer-
ase play an important role in replication. HCV NS3 serine
protease, NS5B RNA-dependent RNA polymerase and
HCV structural proteins are vital targets for antiviral drug
development.
Due to the absence of suitable animal model and com-
petent in-vitro cell culture system the mechanism of HCV
cell entry was unrevealed after a long time. Recently, dif-
ferent groups have studied HCV replication in serum
infected liver cell lines which mimics the naturally occur-
ring HCV virions biology and kinetics of HCV infection in
humans hepatocytes [6-9]. HCV envelop glycoproteins E1
and E2 are involved in HCV entry, fusion and defense
against neutralization by envelop-specific host antibodies
[10-13]. E2 glycoprotein works as a key component in
interaction between the virus and its major cellular recep-
tors i.e., CD81, SR-BI and CLDN1 [13].
CD81 is a 26-kDa surface protein composed of four
hydrophobic transmembrane domains and two hydro-
philic extracellular domains (EC1 and EC2) [14]. Like
other members of the tetraspanin superfamily, CD81 is
expressed in a range of organisms, including mouse and
chimpanzee, and on most human tissues apart from red
blood cells and platelets [15]. The cytoplasmic and
transmembrane domains as well as small extracellular
loop of CD81 are highly conserved between species,
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both in length and sequence, thus contributing to spe-
cies-specific interactions. Cross-linking experiments
have shown that human CD81 mediates a number of
signal transduction events involved in the regulation cell
proliferation, morphology, differentiation, adhesion, and
motility [14]. Human CD81 was identified to interact
with soluble HCV E2 and virus in serum and was pro-
p o s e dt op l a yar o l ei nH C Ve n t r y[ 1 6 , 1 7 ] .H C VE 2
envelop protein interact with CD81, scavenger receptor
type B class 1 protein (SRB-1) and high density lipopro-
tein (HDL) binding molecule [17,18]. CD81 monoclonal
antibody can inhibit entry of HCVpp to cells [19].
The present study was designed to explore the anti-
HCV effect of Host CD81 and HCV specific E2 antibo-
dies. For this purpose, HCVpp of 3a local genotype were
produced by transfecting three vectors in HEK 293 T
cells and were used to infect liver cells in the presence
and absence of host and HCV specific antibodies.
Materials and methods
Serum Sample Collection
HCV-3a patient’s serum sample used in this investigation
was obtained from the CAMB (Center for Applied Mole-
cular Biology) diagnostic laboratory, Lahore, Pakistan.
Serum sample was stored at -80°C prior to viral inocula-
tion experiments. Quantification and genotype was
assessed by CAMB diagnostic laboratory, Lahore, Pakistan.
Patient’s written consent and approval for this study was
obtained from Institutional Ethics Committee.
Cell lines
Huh-7 and HEK 293 T cells were cultured in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with 10%
fetal calf serum, 100 IU/ml penicillin and 100 μg/ml strep-
tomycin, at 37°C in an atmosphere of 5% CO2. Huh-7 cells
were kindly provided by Dr. Zafar Nawaz (Biochemistry
and Molecular Biology Department, University of Miami,
USA). CHO was provided by Dr. Ahmad Usman Zafar
(Biopharmaceutical Lab, CEMB, Pakistan).
Plasmids
The pcDNA-E1E2 expression vector encoding the E1 and
E2 glycoproteins (171-746) of HCV genotype 3a, was gen-
erated by inserting into a nonpackageable, CMV promo-
ter-driven expression construct (provided by Shazia
Rafique, virology lab, CEMB, Pakistan). The CMV-Gag-
Pol murine leukemia virus (MLV) packaging construct,
encoding the MLV gag and pol genes, and the pTG-Luci-
ferase plasmid provided by Dr. Jaean Dubison, France.
Production of HCVpp and infection
HCVpp were produced by co-transfection of 293-T cells
with equal amounts of three expression vectors as
described previously [10]. Supernatants containing
pseudo-particles were harvested 48 h later, filtered
through 0.45 μm pore-sized membranes and stored at
-80°C before use in infection of Huh7 cells in the pre-
sence and absence of CD81 and E2 antibodies.
Inhibition of HCV through host CD81 and HCV specific E2
antibodies
Huh-7 cells were maintained in 6-well culture plates to
semi-confluence, washed twice with serum-free medium
and then HCV E2 antibody and CD81 antibody incu-
bated with liver cells at 37°C for 1 h. After 1 h cells were
infected with 2 × 10
5 copies of HCV 3a genotype per well
and incubated for additional 24 h. After 24 h, cells and
total RNA was isolated by using Gentra RNA isolation
kit (Gentra System Pennsylvania, USA) according to the
manufacturer’s instructions. Briefely, cells were lysed
with cell lysis solution containing 5 μl internal control
(Sacace Biotechnologies Caserta, Italy). RNA pallet was
solubilized in 1% DEPC (Diethyl pyrocarbonate treated
water). HCV RNA quantifications were determined by
Real Time PCR Smart Cycler II system (Cepheid Sunny-
vale, USA) using the Sacace HCV quantitative analysis kit
(Sacace Biotechnologies Caserta, Italy) according to the
manufacturer’s instructions.
Formula for the calculation of HCV RNA concentration
Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3STD/Res
Fam.STD/Res
× coefﬁcient IC = IUHCV/mL
IC = internal control, which is specific for each lot.
Statistical Analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
Results
Anti infectivity effect of CD81 and HCV E2 antibody
against HCVpp and HCV infected serum
In this study, we targeted HCV E2 protein with HCV E2
specific antibody and CD81 receptor with CD81 specific
antibody to check the role of HCV E2 and CD81 receptor
in HCV entry. HCVpp of genotype 3a were incubated
with different concentration of HCV E2 monoclonal anti-
body at 37°C for 1 h and Huh-7 cells were incubated with
different concentration of CD81 antibody at 37°C for 1 h.
After 1 h Huh-7 cells were infected with HCVpp. After
24 h cells were lysed and luciferase activity was deter-
mined by using a luminometer. CD81 antibody exhibited
dose-dependent reduction of HCVpp entry and resulted
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tration and 90% reduction in HCVpp entry at 3 ± 1 μg
concentration as shown in Figure 1a. HCV E2 antibody
also showed dose-dependent reduction of HCVpp entry
and exhibited 50% reduction in HCVpp entry at 1.5 ± 1
μg concentration as shown in Figure 1b. CD81 and HCV
E2 antibody also showed reduction of HCV serum infec-
tivity in liver cells. CD81 and HCV E2 antibody resulted
in 53% and 63% reduction of HCV infected serum
respectively. Moreover, combination of CD81 and HCV
Figure 1 Dose dependent inhibition of HCVpp of 3a genotype. HCVpp was produced in HEK 293 T cells and collected in media after
filtration in 0.45 micron filter.(a) CD81 monoclonal antibody were incubated with Huh-7 cells at 37°C for 1 h. (b) HCV E2 monoclonal antibody
incubated with HCV Pseudo particles at 37°C for 1 hr. After 1 hrs Huh-7 cells were infected with pseudo particle of HCV 3a genotype in the
presence and absence of different concentrations of CD81 and HCV E2 antibody and incubated for 3 hrs. After 24 hrs cells were lysed and
luciferase activity was determined by using a luminometer. Luciferase activity is not reported as an absolute value, but is calculated relative to
the ‘no drug’ condition and reported on the y-axis as a percentage. Results are represented as the average and standard error for three
independent experiments. P value > 0.05 vs control was considered as statistically significant.
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HCV serum infectivity as shown in Figure 2.
Discussion
HCV entry represents an attractive target for drug discov-
ery from a mechanistic point of view, with opportunities
to prevent multiple virus-receptor interactions and to
interfere with virus-cell membrane fusion [20]. Each of
these steps, although not completely defined, is likely
mediated by the HCV E1 and/or E2 envelope glycopro-
teins. In vitro, proof-of-concept for inhibiting the HCV
entry process has been demonstrated using Glanthus niva-
lis Agglutinin (GNA) that targets the N-linked glycans of
the viral envelope proteins and prevents E2-CD81 interac-
tion [21], neutralizing antibodies directed against the HCV
E1 and E2 proteins [22-27], antibodies against cellular
receptors CD81 [9,11,28-31], SR-BI and agents that block
endosomal acidification [32]. In this study, HCVpp of local
HCV genotype 3a were produced to study early entry
steps mediated by HCV envelope glycoproteins. This assay
is based on the quantification of retroviral DNA synthesis,
which occurs soon after the fusion of the retroviral particle
with a cellular membrane. Presumably, this assay is only
dependent on the entry steps mediated by the heterodimer
E1E2 (binding, endocytosis, and fusion) and on the activity
of the reverse transcriptase of the HCVpp retroviral core.
Furthermore, data obtained with HCVpp was also con-
firmed with the infection of whole virus of HCV genotype
3a in liver cells.
Previous evidence suggests that cell-mediated immunity
play an important role in clearance and control of HCV
replication in acute infection [33]. It is not necessary that
all antibodies of HCV E2 envelop protein inhibit virus
entry by neutralization of viral infection. However, major-
ity of E2 antibodies that demonstrated broad neutraliza-
tion of infection are directed against conformational
epitopes within E2 envelop protein [26,27]. Our data
showed that antibodies against HCV E2 envelop protein
inhibit HCV entry of 3a local genotype in a dose-depen-
dent manner and resulted in 50% reduction in HCVpp
entry at a concentration of 1.5 ± 1 μg.
HCV entry is a multiple-step process and several host
proteins have been identified as receptors, including
CD81, SRBI, Claudin I and occludin [31,34,35]. In this
study we showed that CD81 is required for HCV glycopro-
tein dependent entry of HCVpp. Our data exhibited that
HCVpp entry is blocked in hepatoma cell line with CD81
specific monoclonal antibody. Several reports also illu-
strated that CD81 is required for HCVpp entry. Silencing
CD81 with CD81 specific siRNA has blocked entry of
HCVpp [28].
HCV infects liver cells, replicates efficiently and con-
tinuously in liver derived Huh-7 cells [36]. Huh-7 cells
are most widely used for liver associated diseases and
fundamental studies for the development of antiviral
agents against HCV as infectious cell culture system
[10,37-39]. Recently different groups have studied the
HCV replication in serum infected liver cell lines which
mimics the naturally occurring HCV virions biology and
kinetics of HCV infection in human. We infected Huh-7
cells with native viral particles from HCV-3a positive
serum using the same protocol as describe by El-Awady
et al., and Zekri et al [7,40]. Our data proved that CD81
and HCV E2 antibody exhibited 53% and 63% reduction
Figure 2 Antiviral effect of CD81 and HCV E2 antibodies against HCV 3a genotype in liver cells. HCV E2 antibody was incubated with 2 ×
10
5 HCV 3a virus and CD81 antibody incubated with liver cells at 37°C for I h. After 1 h cells were infected with 2 × 10
5 copies of HCV 3a
genotype per well and incubated for additional 24 h. At the end of incubation period, total RNA was extracted by Gentra kit, and the levels of
HCV RNA remaining were determined, by real time Quantitative RT-PCR assay and are shown as percentage of HCV RNA survival in cells. Results
are represented as the average and standard error for three independent experiments. P value > 0.05 vs control was considered as statistically
significant.
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nation of CD81 and HCV E2 antibody synergistically
showed 91% reduction of HCV serum infectivity.
Conclusion
In conclusion, our results demonstrated that HCV E2
and host CD81 dose dependently inhibit HCVpp and
full length viral particle entry in liver cells. Moreover,
combination of E2 and CD81 antibodies showed syner-
gistic effect in preventing HCV infection.
Abbreviations
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